I think it also speaks volumes that ZEN-3694 is the only epigenetc drug in NIH sponsored cancer trials (according to Don) and likewise the fact that the UCSF/Merck mCRPC trial is investigator sponsored says a lot about the prospects for the drug. In a quick look I didn't see any of that kind of validation on Constellation's website/pipeline info, but they are entering ph 3 with their drug. Additionally, according to the latest Zenith presentations some of their studies are registration enabling.